stockrowAlnylam Pharmaceuticals, Inc. (ALNY) vs Roivant Sciences Ltd. (ROIV)
- Alnylam Pharmaceuticals, Inc. ALNY 156.28 −0.24%
- Roivant Sciences Ltd. ROIV 38.90 +6.23%
Alnylam Pharmaceuticals, Inc. and Roivant Sciences Ltd. are both Biotechnology companies. Roivant Sciences Ltd. is the larger, with a market value of $26.5B against $21.0B — 1.3× the size. Roivant Sciences Ltd. has negative trailing earnings, so its P/E is not meaningful; Alnylam Pharmaceuticals, Inc. trades at 7.9×. Alnylam Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 56.2% against −67.6%. Alnylam Pharmaceuticals, Inc. has the higher net margin (52.9% vs −3,535.0%) and the higher return on invested capital (59.4% vs −34.5%). Across the 18 metrics below, Alnylam Pharmaceuticals, Inc. leads on 14 and Roivant Sciences Ltd. on 4.
Valuation
Profitability
| Metric | ALNY | ROIV | Biotechnology median |
|---|---|---|---|
| Gross margin | 77.28% | 81.21% | 68.51% |
| Operating margin | 19.50% | (7,914.75%) | 0.00% |
| Net margin | 52.85% | (3,534.96%) | 0.00% |
| Free cash flow margin | 16.08% | (10,901.00%) | 0.00% |
| Return on equity | 138.07% | (5.47%) | (51.96%) |
| Return on assets | 41.25% | (5.15%) | (46.06%) |
| Return on invested capital | 59.37% | (34.51%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack